Analysts who follow ZIOPHARM Oncology Inc. (ZIOP) on average expect it to gain 216.60% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns ZIOPHARM Oncology Inc. an Analyst Ranking of 15, which means it ranks higher than 15 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating ZIOP a Buy today. Find out what this means to you and get the rest of the rankings on ZIOP!